Brokers Set Expectations for C4 Therapeutics Q3 Earnings

Key Points

• Brookline Capital Markets raised its Q3 2026 EPS estimate for C4 Therapeutics to a loss of $0.20 per share from a previous estimate of $0.21, while projecting losses of $0.80, $0.93 and $1.64 per share for fiscal 2026–2028.
• C4 Therapeutics reported a quarterly loss of $0.18 per share, beating the consensus loss estimate of $0.23, while revenue of $6.64 million exceeded expectations of $4.00 million.
• The stock opened at $3.90, up 0.8%, and analysts maintain a “Moderate Buy” consensus with an average price target of $7.75; institutional investors own 78.81% of the shares.

C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) - Equities research analysts at Brookline Capital Markets boosted their Q3 2026 earnings per share (EPS) estimates for C4 Therapeutics in a research note issued on Tuesday, August 11th. Brookline Capital Markets analyst L. Cann now expects that the company will earn ($0.20) per share for the quarter, up from their previous estimate of ($0.21). The consensus estimate for C4 Therapeutics' current full-year earnings is ($0.87) per share. Brookline Capital Markets also issued estimates for C4 Therapeutics' FY2026 earnings at ($0.80) EPS, FY2027 earnings at ($0.93) EPS and FY2028 earnings at ($1.64) EPS.

Separately, Weiss Ratings restated a "sell (d-)" rating on shares of C4 Therapeutics in a research report on Friday, July 17th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $7.75.

C4 Therapeutics Stock Up 0.8%

Shares of NASDAQ CCCC opened at $3.90 on Thursday. The company has a market cap of $431.22 million, a P/E ratio of -3.90 and a beta of 2.91. C4 Therapeutics has a 52 week low of $1.69 and a 52 week high of $5.17. The business has a 50-day simple moving average of $3.90 and a two-hundred day simple moving average of $3.17.

C4 Therapeutics (NASDAQ:CCCC - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.05. The firm had revenue of $6.64 million for the quarter, compared to analysts' expectations of $4.00 million. C4 Therapeutics had a negative return on equity of 47.15% and a negative net margin of 289.44%.

Institutional Trading of C4 Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC raised its holdings in C4 Therapeutics by 53.6% during the 1st quarter. Renaissance Technologies LLC now owns 2,461,815 shares of the company's stock valued at $6,475,000 after buying an additional 859,235 shares during the last quarter. Stempoint Capital LP bought a new stake in C4 Therapeutics in the 1st quarter worth $1,192,000. Wasatch Advisors LP increased its position in shares of C4 Therapeutics by 18.9% in the second quarter. Wasatch Advisors LP now owns 3,522,644 shares of the company's stock valued at $16,451,000 after acquiring an additional 560,883 shares during the period. Seven Fleet Capital Management LP bought a new position in shares of C4 Therapeutics during the first quarter valued at about $150,000. Finally, Sei Investments Co. purchased a new stake in shares of C4 Therapeutics during the first quarter worth about $66,000. Institutional investors own 78.81% of the company's stock.

About C4 Therapeutics

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body's natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company's pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source